top of page
Search
  • Writer's pictureARQon
    • Apr 5, 2017
    • 1 min read

Europe - April 2017

  • Europe: Latest timings on the new Regulations for medical devices and IVDs

  • Europe: Products whose principal intended action (depending on PAC present in cranberry) is to prevent or treat cystitis, should not be medical devices

  • Europe: Joint Action on Market Surveillance of Medical Devices launched at 39th CAMD meeting

  • Europe: Eucomed and EDMA formally merge to create MedTech Europe

  • France: Advice for French manufacturers if their Notified Bodies cease operations

  • Sweden: Responsibility for Notified Bodies to transfer to MPA from SWEDAC

  • Switzerland: Grace period for manufacturers affected by the de-designation of their Notified Body

  • UK: Significant fee increases proposed by MHRA to aid cost recovery

Click here for the full article on Global Regulatory Press.

Contact us at info@arq-on.com.


10 views0 comments

Recent Posts

See All

Europe - May 2020

Denmark: New rules mean non-serious adverse events may also need to be reported EU: Application of Regulation (EU) 2017/745 postponed by one year EU: Continued use of lead as a thermal stabiliser in P

EU: MDR delayed to 26 May 2021

Application of the Medical Devices Regulation (MDR) has been deferred by one year, until 26 May 2021, for fear of shortage or delay in getting essential medical devices needed to combat Covid-19. The

EU 2020 MDR Guidance Notes For Class I Manufacturers

There will be no transition period for Class I medical devices which remain in Class I under MDR. From 26th May 2020 onwards, the conformity for Class I medical devices which are not subject to up-cla

bottom of page